27-12-2012 дата публикации
Номер: US20120329798A1
Автор:
Mhairi Copland,
Marion Dorsch,
David Irvine,
Paul W. Manley,
Stefan Peukert,
COPLAND MHAIRI,
DORSCH MARION,
IRVINE DAVID,
MANLEY PAUL W,
PEUKERT STEFAN,
MANLEY PAUL W.
Принадлежит:
A combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia. 2. The combination of claim 1 , wherein said first agent is 2-methyl-4′-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2 claim 1 ,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide or a pharmaceutically acceptable salt thereof.3. The combination of claim 1 , wherein said first agent is 2-[(R)-4-(6-benzyl-4 claim 1 ,5-dimethyl-pyridazin-3-yl)-2-methyl-3 claim 1 ,4 claim 1 ,5 claim 1 ,6-tetrahydro-2H-[1 claim 1 ,2]bipyrazinyl-5′-yl]-propan-2-ol or a pharmaceutically acceptable salt thereof.4. The combination of claim 1 , wherein said second agent is an ABL inhibitor claim 1 , an ABL/Scr inhibitor claim 1 , an Aurora kinase inhibitor claim 1 , or a non-ATP competitive inhibitor of BCR-ABL.5. The combination of claim 1 , wherein said second agent is selected from the group consisting of nilotinib (AMN107) claim 1 , imatinib (STI571) claim 1 , 2 claim 1 ,6 claim 1 ,9-trisubstituted purine analogs (e.g. claim 1 , AP23464) claim 1 , AZD-0530 claim 1 , bosutinib (SKI-606) claim 1 , CPG070603 claim 1 , pyrido[2 claim 1 ,3-d]pyrimidine compounds (e.g. claim 1 , dasatinib (BMS-354825)) claim 1 , PD166326 claim 1 , PD173955 claim 1 , PD180970) claim 1 , ON012380 claim 1 , 3-substituted benzamide derivatives (e.g. claim 1 , INNO-406) claim 1 , MK-0457 (VX-680) claim 1 , PHA-739358 claim 1 , retaspimycin hydrochloride (IPI-504) and GNF-2.6. The combination of claim 5 , wherein the second agent is nilotinib.7. The combination of claim 6 , wherein the first agent is 2-methyl-4′-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2 claim 6 ,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide or a pharmaceutically acceptable salt thereof.8. The combination of claim 6 , wherein the first agent is 2-[(R)-4-(6-benzyl-4 claim 6 ,5-dimethyl-pyridazin-3-yl)-2-methyl-3 claim 6 ,4 claim 6 ,5 claim 6 ,6-tetrahydro-2H-[1 claim 6 ,2′]bipyrazinyl-5′-yl]-propan-2-ol or a pharmaceutically acceptable ...
Подробнее